Pheon Therapeutics Launches with $68 Million in Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Solid Tumors
Aims to advance its lead ADC compound targeting a novel cancer antigen
04-Oct-2022 -
Pheon Therapeutics (Pheon), a Antibody-Drug Conjugate(ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched following the closing of a $68 million Series A financing in March 2022. The investment will enable Pheon to advance its lead ADC program to ...
antibody-drug conjugate
cancer
Series A financing